Connect with us

Health

World Marks 37th World AIDS Day as Funding Cuts Raise Fears of Setbacks in Global Fight Against HIV

Published

on

An estimated 40.8 million people are living with HIV worldwide, and the virus claimed about 630,000 lives last year, according to new global health figures released as the world observed the 37th World AIDS Day on Sunday. The annual commemoration, held every 1 December since 1988, brings together scientists, health workers, families and advocates to honour victims and renew the push to end one of the deadliest epidemics in modern history.

Since the start of the crisis, HIV has infected about 91.4 million people and caused approximately 44.1 million deaths. Despite decades of scientific advancement, experts warn that progress could be at risk as several major donor nations scale back support for international HIV programmes.

The global response to HIV began gaining momentum in the early 1980s, when US health officials identified a mysterious and fatal illness among young gay men. The disease, later understood to be caused by HIV, soon spread across different communities, from people who used drugs to haemophiliacs and blood transfusion recipients. Europe launched its first AIDS surveillance system in 1984, and by late 1985 HIV testing became available in the UK.

A turning point came in 1996 with the introduction of highly active antiretroviral therapy, or HAART, a three-drug combination that suppressed the virus and restored immune function. This breakthrough sharply reduced AIDS-related deaths in countries able to afford the treatment and shifted HIV from a near-certain death sentence to a chronic but manageable condition.

In 2003, the United States introduced the President’s Emergency Plan for AIDS Relief (PEPFAR), a landmark $15 billion programme aimed at high-burden countries. As of 2025, PEPFAR has been credited with saving more than 26 million lives across 50 nations, making it the largest single-disease global health programme in history.

See also  Study Finds Deep, Long-Lasting Grief Can Raise Risk of Death by Nearly 90% Over a Decade

Scientific progress continued into the next decade. In 2011, researchers confirmed that antiretroviral therapy significantly reduces the risk of transmitting HIV. A year later, US regulators approved Truvada as the first drug for pre-exposure prophylaxis (PrEP), followed by the EU in 2016. PrEP has since become a cornerstone of prevention, shown to reduce infection risk from sex by about 99% and from injections by roughly 74%. These tools helped drive HIV diagnoses among gay and bisexual men in the UK down by two-thirds between 2015 and 2020.

But global gaps remain. The UN’s 90-90-90 targets—set for 2020 and aimed at ensuring that 90% of people with HIV know their status, receive treatment, and achieve viral suppression—were fully met by only 19 countries. Sweden was the first to reach the milestones in 2016.

Recent advances, including a twice-yearly PrEP injection approved in the EU in 2024, have been hailed as potential game-changers. Plans are underway to bring generic versions to lower-income nations by 2027.

This year, however, health agencies have sounded the alarm over abrupt US aid freezes and funding reductions from several European governments, including the UK, Germany and France. Experts warn the cuts threaten to reverse gains in HIV prevention and treatment, especially in Africa, which accounts for more than two-thirds of all infections.

As World AIDS Day is marked once again, global health leaders stress that decades of progress cannot be sustained without consistent international support.

Health

Growing Research Links Tattoos to Possible Cancer Risks, Experts Say

Published

on

Tattoos are more popular than ever, but a growing body of research suggests a connection between permanent ink and certain types of cancer. How concerned should the public be?

From tribal sleeves to lower-back butterflies, humans have been inking their skin for thousands of years. For most, the main concern has been the fear of future regrets. However, recent studies suggest that tattoos could carry more serious long-term health risks.

The popularity of tattoos has risen sharply in recent years. Research published in the European Journal of Public Health estimates that between 13 and 21 percent of people in Western Europe now have at least one tattoo. Despite this prevalence, relatively little is known about the potential long-term effects of permanent ink.

Previous studies have shown that tattoo pigments can accumulate in the lymph nodes, sometimes causing inflammation and, in rare cases, lymphoma—a type of blood cancer. A 2025 study by the University of Southern Denmark (SDU) expanded on this, reporting that individuals with tattoos may face higher risks of skin cancer and lymphoma. Using a cohort of randomly selected twins, the researchers found that tattooed participants had nearly four times the risk of skin cancer compared with their non-tattooed siblings.

The study also suggested that tattoo size could affect risk, with designs larger than the palm associated with higher hazard rates.

“We have evidence that there is an association [between the amount of ink and risk] for lymphoma and for skin cancer,” said Signe Bedsted Clemmensen, co-author of the study and assistant professor of biostatistics at SDU. “For lymphoma, the hazard rate is 2.7 times higher, so this is quite a lot. And for skin cancers, before it was 1.6 and now it’s 2.4. This indicates that the more ink you have, the higher the risk, the higher the hazard rate.”

See also  Measles Outbreaks Surge Across Europe, Romania Hit Hardest

Clemmensen emphasized that these findings remain preliminary, with many variables—including ink types, tattoo placement, and genetic and environmental factors—still under investigation. “The bottom line is, more research is needed,” she said. “But also, the next step I think is studying the biological mechanisms [of getting tattooed] and trying to understand what happens there.”

Experts also note other risks unrelated to cancer. Tattoo inks consist of pigments combined with a carrier fluid to deposit color into the dermis. Some inks, often imported, can contain trace amounts of heavy metals such as nickel, chromium, cobalt, and lead, which can trigger allergic reactions or immune sensitivity. In 2022, the European Union restricted more than 4,000 hazardous substances in tattoo inks under its REACH regulations.

While tattoos are generally considered safe when applied hygienically, the long-term health consequences remain uncertain. “It’s up to each of us how we choose to live our lives, right? But as a researcher, it’s also my job to inform people of these risks,” Clemmensen said. “Or, when it comes to tattooing, right now it’s more about informing people about how little we know.”

Continue Reading

Health

Researchers Identify Enzyme as Potential Target to Slow Alzheimer’s Memory Loss

Published

on

Scientists have identified a potential new approach to slow memory loss in Alzheimer’s disease, offering hope for treatments that could improve the lives of millions affected by the neurodegenerative disorder.

Researchers at Cold Spring Harbor Laboratory, a non-profit research institution in New York, found that an enzyme called PTP1B contributes to memory decline in mice with Alzheimer’s. The study reveals a previously unknown role for the enzyme in immune cell signaling and suggests it could be a promising target for therapy.

Nicholas Tonks, a professor at the laboratory and the study’s corresponding author, discovered PTP1B in 1988 and has since explored its role in health and disease. Tonks and his team found that reducing PTP1B activity improved the ability of the brain’s immune cells, known as microglia, to clear amyloid-β (Aβ) plaques. These protein accumulations are a hallmark of Alzheimer’s disease and contribute to neuronal damage. Normally, microglia remove debris in the brain, but their function declines as the disease progresses.

The researchers discovered that PTP1B interacts with a protein called spleen tyrosine kinase (SYK), which regulates microglial responses to damage and plaque clearance.

“Over the course of the disease, these cells become exhausted and less effective,” said Yuxin Cen, the study lead. “Our results suggest that PTP1B inhibition can improve microglial function, clearing up Aβ plaques.”

PTP1B is also known for its role in metabolic conditions such as obesity and type 2 diabetes, which are recognized risk factors for Alzheimer’s disease. Researchers are now working to develop PTP1B inhibitors for multiple applications, including as a potential therapy for the neurodegenerative condition.

See also  Mediterranean Diet Linked to Lower Dementia Risk, Study Finds

Tonks envisions combining PTP1B inhibitors with existing approved drugs for Alzheimer’s, such as cholinesterase inhibitors like donepezil or NMDA receptor antagonists such as memantine, used for more advanced stages.

“The goal is to slow Alzheimer’s progression and improve the quality of life of the patients,” Tonks said. He added that the research is particularly personal: “It’s a slow bereavement. You lose the person piece by piece,” recalling his mother’s experience with the disease.

According to the World Health Organization, more than 55 million people live with dementia globally, with Alzheimer’s accounting for up to 70 percent of cases. Current treatments manage symptoms but do not halt disease progression, making the search for new therapies critical.

The Cold Spring Harbor Laboratory team says their findings open the door to a new pathway for treatment, targeting the immune system’s capacity to remove harmful plaques. Researchers are hopeful that continued development of PTP1B inhibitors could complement existing drugs and slow the devastating effects of Alzheimer’s, potentially transforming care for millions worldwide.

Continue Reading

Health

Health Experts Offer Tips for Safe Travel During Winter Olympics in Italy

Published

on

As the Winter Olympics 2026 get underway in Milan and Cortina, experts are urging visitors to take health precautions to ensure a safe and enjoyable stay. The games, running from February 6 to 22, will draw thousands of spectators from around the world, increasing the risk of illness transmission in crowded venues.

Respiratory viruses, including influenza and COVID-19, remain active across Europe this winter. Health authorities recommend vaccination, particularly for high-risk groups such as the elderly, pregnant women, young children, and individuals with chronic conditions. Good hand hygiene, use of alcohol-based sanitizers, and avoiding close contact with sick individuals are also advised. Travellers who develop symptoms during their stay are encouraged to wear masks in public, remain indoors, and minimize contact with others where possible.

The European Centre for Disease Prevention and Control (ECDC) also advises visitors to check their vaccination status before travelling. Routine immunisations may require adult boosters, with priority given to measles vaccines due to rising global outbreaks, including in parts of Europe. Travellers are advised to complete vaccinations at least two weeks prior to departure and to carry necessary medications and treatments during their trip.

Food safety is another key consideration for visitors. Most illnesses among travellers result from consuming spoiled food or contaminated drinks. Experts recommend eating thoroughly cooked meals, washing fresh fruits and vegetables, and avoiding perishable foods that have been left at room temperature for more than two hours. Tap water in Milan and Cortina is considered safe for drinking.

Large gatherings, such as the Olympic events, can also increase the risk of sexually transmitted infections (STIs). Common infections in Europe include chlamydia, gonorrhoea, and syphilis, while HIV, viral hepatitis, and mpox can also be transmitted through sexual contact. Health professionals recommend discussing personal risk assessments with a healthcare provider before travel, including the possible use of pre-exposure prophylaxis (PrEP) for HIV and vaccines for hepatitis A, hepatitis B, and mpox. Travellers should get tested for STIs if they have had unprotected sex or multiple partners, even without symptoms.

See also  Mediterranean Diet Linked to Lower Dementia Risk, Study Finds

By following these measures, visitors can enjoy the Winter Olympics while minimizing health risks. Authorities emphasize that vaccinations, hygiene, safe food and drink practices, and responsible sexual health behaviours remain essential for a safe trip during large international events.

“The Winter Olympics are an exciting opportunity to celebrate sport and culture,” experts said. “But taking simple health precautions can make the difference between a memorable trip and a preventable illness.”

Continue Reading

Trending